Fig. 3From: Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s diseaseDisposition of patients. BID twice daily, QD once dailyBack to article page